Advertisement


Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials

2018 Gastrointestinal Cancers Symposium

Advertisement

Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer (Abstracts 553, 554).



Related Videos

Gastroesophageal Cancer

Basem Azab, MD, on Esophageal Cancer: Study Survival Results

Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadju...

Pancreatic Cancer
Immunotherapy

Steven D. Leach, MD, on Pancreatic Cancer: Keynote Lecture

Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—i...

Gastroesophageal Cancer

David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent resu...

Hepatobiliary Cancer
Immunotherapy

Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224

Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sora...

Gastrointestinal Cancer
Immunotherapy

Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial

Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...

Advertisement

Advertisement



Advertisement